{
    "id": 79,
    "premise": "none",
    "hypothesis": "Patient may benefit from combination vemurafenib and chemotherapy.",
    "label": "entailment",
    "explanation": "Patient with TNBC not appropriate for immunotherapy or PARP inhibitors as second line therapy.\nCombination vemurafenib and MEK inhibitor unavailable for patient.\nThe combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and\u00a0BRAFV600\u00a0mutations irrespective of prior treatment with BRAF and/or MEK inhibitors.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Patient may benefit from combination vemurafenib and chemotherapy.",
        "refined explanation": "The combination of vemurafenib, carboplatin, and paclitaxel being well tolerated implies that the patient may benefit from a treatment involving vemurafenib and chemotherapy.\nThe patient benefiting from a treatment involving vemurafenib and chemotherapy is directly related to the well-tolerated nature of the combination of vemurafenib, carboplatin, and paclitaxel.",
        "refined iteration": 1,
        "history explanation": [
            "0 iteration: Patient with TNBC not appropriate for immunotherapy or PARP inhibitors as second line therapy.\nCombination vemurafenib and MEK inhibitor unavailable for patient.\nThe combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and\u00a0BRAFV600\u00a0mutations irrespective of prior treatment with BRAF and/or MEK inhibitors.",
            "1 iteration: The combination of vemurafenib, carboplatin, and paclitaxel being well tolerated implies that the patient may benefit from a treatment involving vemurafenib and chemotherapy.\nThe patient benefiting from a treatment involving vemurafenib and chemotherapy is directly related to the well-tolerated nature of the combination of vemurafenib, carboplatin, and paclitaxel."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* There is an explanation that the combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity. *)\\n(* There is a logical relation Implies(E, F), Implies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity) *)\\n(* Since the patient is x, we can infer that the patient may benefit from the combination of vemurafenib and chemotherapy. *)\\nthen have \"\u2203e. BenefitFrom e \u2227 CombinationVemurafenibChemotherapy e \u2227 Agent e x\" sledgehammer', 'solving time': 104.53033208847046, 'proof tactics': [], 'code': 'theory clinical_79_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  TNBC :: \"entity \u21d2 bool\"\\n  AppropriateForImmunotherapy :: \"entity \u21d2 bool\"\\n  AppropriateForPARPInhibitors :: \"entity \u21d2 bool\"\\n  CombinationVemurafenibMEKInhibitor :: \"event \u21d2 bool\"\\n  Unavailable :: \"event \u21d2 bool\"\\n  WellTolerated :: \"event \u21d2 bool\"\\n  DemonstratesActivity :: \"event \u21d2 bool\"\\n  CombinationVemurafenibCarboplatinPaclitaxel :: \"event \u21d2 bool\"\\n  PredominantlyAdvancedMelanomaBRAFV600Mutations :: \"event \u21d2 bool\"\\n  IrrespectiveOfPriorTreatment :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patient with TNBC not appropriate for immunotherapy or PARP inhibitors as second line therapy *)\\naxiomatization where\\n  explanation_1: \"\u2203x. Patient x \u2227 TNBC x \u2227 \u00ac(AppropriateForImmunotherapy x \u2228 AppropriateForPARPInhibitors x)\"\\n\\n(* Explanation 2: Combination vemurafenib and MEK inhibitor unavailable for patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x e. Patient x \u2227 Unavailable e \u2227 CombinationVemurafenibMEKInhibitor e \u2227 Patient x\"\\n\\n(* Explanation 3: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations irrespective of prior treatment *)\\naxiomatization where\\n  explanation_3: \"\u2203e. WellTolerated e \u2227 DemonstratesActivity e \u2227 CombinationVemurafenibCarboplatinPaclitaxel e \u2227 PredominantlyAdvancedMelanomaBRAFV600Mutations e \u2227 IrrespectiveOfPriorTreatment e\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy *)\\n shows \"\u2203x e. Patient x \u2227 BenefitFrom e \u2227 CombinationVemurafenibChemotherapy e \u2227 Agent e x\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is an explanation that the combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity. *)\\n  (* There is a logical relation Implies(E, F), Implies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity) *)\\n  (* Since the patient is x, we can infer that the patient may benefit from the combination of vemurafenib and chemotherapy. *)\\n  then have \"\u2203e. BenefitFrom e \u2227 CombinationVemurafenibChemotherapy e \u2227 Agent e x\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with TNBC\\nB: appropriate for immunotherapy\\nC: appropriate for PARP inhibitors\\nD: Combination vemurafenib and MEK inhibitor available for patient\\nE: Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated\\nF: Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity\\nG: predominantly in patients with advanced melanoma\\nH: BRAFV600 mutations\\nI: irrespective of prior treatment with BRAF and/or MEK inhibitors\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies(Patient with TNBC, Not(appropriate for immunotherapy))\\n--------\\nImplies(A, Not(C))\\nImplies(Patient with TNBC, Not(appropriate for PARP inhibitors))\\n--------\\nNot(D)\\nNot(Combination vemurafenib and MEK inhibitor available for patient)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(Combination vemurafenib and MEK inhibitor available for patient), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(E, F)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity)\\n--------\\nImplies(F, G)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity, predominantly in patients with advanced melanoma)\\n--------\\nImplies(G, H)\\nImplies(predominantly in patients with advanced melanoma, BRAFV600 mutations)\\n--------\\nImplies(H, I)\\nImplies(BRAFV600 mutations, irrespective of prior treatment with BRAF and/or MEK inhibitors)\\n--------\\n\\nDerived Implications:\\nImplies(Not(F), Not(D))\\nImplies(Not(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, F)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity)\\n--------\\nImplies(F, Not(D))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(BRAFV600 mutations), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(G, Not(D))\\nImplies(predominantly in patients with advanced melanoma, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, Not(E))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Patient with TNBC), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(E, I)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, irrespective of prior treatment with BRAF and/or MEK inhibitors)\\n--------\\nImplies(C, Not(E))\\nImplies(appropriate for PARP inhibitors, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(E, Not(I))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(irrespective of prior treatment with BRAF and/or MEK inhibitors))\\n--------\\nImplies(B, Not(D))\\nImplies(appropriate for immunotherapy, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(F, I)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity, irrespective of prior treatment with BRAF and/or MEK inhibitors)\\n--------\\nImplies(E, H)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, BRAFV600 mutations)\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(predominantly in patients with advanced melanoma), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(E, Not(C))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(appropriate for PARP inhibitors))\\n--------\\nImplies(E, Not(A))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(Patient with TNBC))\\n--------\\nImplies(F, H)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity, BRAFV600 mutations)\\n--------\\nImplies(G, I)\\nImplies(predominantly in patients with advanced melanoma, irrespective of prior treatment with BRAF and/or MEK inhibitors)\\n--------\\nImplies(D, A)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Patient with TNBC)\\n--------\\nImplies(D, B)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, appropriate for immunotherapy)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(appropriate for immunotherapy), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(H, Not(D))\\nImplies(BRAFV600 mutations, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, Not(B))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(appropriate for immunotherapy))\\n--------\\nImplies(E, Not(E))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(appropriate for PARP inhibitors), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(I, Not(E))\\nImplies(irrespective of prior treatment with BRAF and/or MEK inhibitors, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(A, Not(D))\\nImplies(Patient with TNBC, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(Not(I), Not(E))\\nImplies(Not(irrespective of prior treatment with BRAF and/or MEK inhibitors), Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(D, G)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, predominantly in patients with advanced melanoma)\\n--------\\nImplies(D, C)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, appropriate for PARP inhibitors)\\n--------\\nImplies(F, Not(E))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(BRAFV600 mutations), Not(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity))\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(BRAFV600 mutations), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, Not(G))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(predominantly in patients with advanced melanoma))\\n--------\\nImplies(C, Not(D))\\nImplies(appropriate for PARP inhibitors, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(G, Not(E))\\nImplies(predominantly in patients with advanced melanoma, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Patient with TNBC), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, Not(H))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(BRAFV600 mutations))\\n--------\\nImplies(D, Not(F))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity))\\n--------\\nImplies(E, A)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Patient with TNBC)\\n--------\\nImplies(D, Not(C))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(appropriate for PARP inhibitors))\\n--------\\nImplies(E, B)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, appropriate for immunotherapy)\\n--------\\nImplies(B, Not(E))\\nImplies(appropriate for immunotherapy, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(predominantly in patients with advanced melanoma), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, E)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated)\\n--------\\nImplies(E, Not(B))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(appropriate for immunotherapy))\\n--------\\nImplies(E, G)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, predominantly in patients with advanced melanoma)\\n--------\\nImplies(E, C)\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, appropriate for PARP inhibitors)\\n--------\\nImplies(Not(I), Not(D))\\nImplies(Not(irrespective of prior treatment with BRAF and/or MEK inhibitors), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, I)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, irrespective of prior treatment with BRAF and/or MEK inhibitors)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(E, Not(G))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(predominantly in patients with advanced melanoma))\\n--------\\nImplies(D, Not(I))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(irrespective of prior treatment with BRAF and/or MEK inhibitors))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(appropriate for immunotherapy), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(D, H)\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, BRAFV600 mutations)\\n--------\\nImplies(Not(I), Not(G))\\nImplies(Not(irrespective of prior treatment with BRAF and/or MEK inhibitors), Not(predominantly in patients with advanced melanoma))\\n--------\\nImplies(D, Not(A))\\nImplies(Combination vemurafenib and MEK inhibitor available for patient, Not(Patient with TNBC))\\n--------\\nImplies(H, Not(E))\\nImplies(BRAFV600 mutations, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(E, Not(F))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity))\\n--------\\nImplies(E, Not(D))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(appropriate for PARP inhibitors), Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(I, Not(D))\\nImplies(irrespective of prior treatment with BRAF and/or MEK inhibitors, Not(Combination vemurafenib and MEK inhibitor available for patient))\\n--------\\nImplies(A, Not(E))\\nImplies(Patient with TNBC, Not(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated))\\n--------\\nImplies(Not(I), Not(F))\\nImplies(Not(irrespective of prior treatment with BRAF and/or MEK inhibitors), Not(Combination of vemurafenib, carboplatin, and paclitaxel demonstrates encouraging activity))\\n--------\\nImplies(E, Not(H))\\nImplies(Combination of vemurafenib, carboplatin, and paclitaxel is well tolerated, Not(BRAFV600 mutations))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 12.913146257400513, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'verit found a proof...', 'cvc4 found a proof...', 'verit: Try this: using explanation_1 by blast (0.4 ms)', 'e found a proof...', 'vampire found a proof...', 'cvc4 found a proof...', 'e: Found duplicate proof', 'zipperposition: Found duplicate proof', 'zipperposition found a proof...', 'zipperposition found a proof...', 'cvc4: Try this: using explanation_1 by fastforce (1 ms)', 'vampire: Found duplicate proof', 'cvc4: Try this: using explanation_1 by force (1 ms)', 'zipperposition: Found duplicate proof', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_79_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient may benefit from combination vemurafenib and chemotherapy *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Patient x \u2227 Combination y \u2227 Vemurafenib y \u2227 Chemotherapy y \u2227 Benefit e \u2227 Agent e x \u2227 Patient x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Combination y \u2227 Vemurafenib y \u2227 Chemotherapy y\"\\n  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy *)\\n shows \"\u2203x y e. Patient x \u2227 Combination y \u2227 Vemurafenib y \u2227 Chemotherapy y \u2227 Benefit e \u2227 Agent e x \u2227 Patient x\"\\nproof -\\n  (* From the premise, we have information about the patient, combination, vemurafenib, and chemotherapy. *)\\n  from asm have \"Patient x \u2227 Combination y \u2227 Vemurafenib y \u2227 Chemotherapy y\" <ATP>\\n  (* There is a logical relation Implies(C, A), Implies(patient benefiting from a treatment involving vemurafenib and chemotherapy, combination of vemurafenib, carboplatin, and paclitaxel being well tolerated) *)\\n  (* We can infer that the combination of vemurafenib, carboplatin, and paclitaxel being well tolerated. *)\\n  then have \"Patient x \u2227 Combination y \u2227 Vemurafenib y \u2227 Chemotherapy y \u2227 Benefit e \u2227 Agent e x \u2227 Patient x\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: combination of vemurafenib, carboplatin, and paclitaxel being well tolerated\\nB: patient may benefit from a treatment involving vemurafenib and chemotherapy\\nC: patient benefiting from a treatment involving vemurafenib and chemotherapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(combination of vemurafenib, carboplatin, and paclitaxel being well tolerated, patient may benefit from a treatment involving vemurafenib and chemotherapy)\\n--------\\nImplies(C, A)\\nImplies(patient benefiting from a treatment involving vemurafenib and chemotherapy, combination of vemurafenib, carboplatin, and paclitaxel being well tolerated)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(C))\\nImplies(Not(patient may benefit from a treatment involving vemurafenib and chemotherapy), Not(patient benefiting from a treatment involving vemurafenib and chemotherapy))\\n--------\\nImplies(C, B)\\nImplies(patient benefiting from a treatment involving vemurafenib and chemotherapy, patient may benefit from a treatment involving vemurafenib and chemotherapy)\\n--------\\n'}"
        ]
    }
}